<code id='131274BFEF'></code><style id='131274BFEF'></style>
    • <acronym id='131274BFEF'></acronym>
      <center id='131274BFEF'><center id='131274BFEF'><tfoot id='131274BFEF'></tfoot></center><abbr id='131274BFEF'><dir id='131274BFEF'><tfoot id='131274BFEF'></tfoot><noframes id='131274BFEF'>

    • <optgroup id='131274BFEF'><strike id='131274BFEF'><sup id='131274BFEF'></sup></strike><code id='131274BFEF'></code></optgroup>
        1. <b id='131274BFEF'><label id='131274BFEF'><select id='131274BFEF'><dt id='131274BFEF'><span id='131274BFEF'></span></dt></select></label></b><u id='131274BFEF'></u>
          <i id='131274BFEF'><strike id='131274BFEF'><tt id='131274BFEF'><pre id='131274BFEF'></pre></tt></strike></i>

          focus

          focus

          author:comprehensive    Page View:55396
          First Opinion Podcast

          Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

          While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

          advertisement

          But Hughes has a better idea for how to not only protect but also expand access to PrEP.

          On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

          “If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

          advertisement

          Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

          Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

          And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Readout Newsletter: XBI biotech index, Akero Therapeutics
          Readout Newsletter: XBI biotech index, Akero Therapeutics

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          STAT Wunderkinds: Ruey Hu's digital tools for parsing research

          HugraduatingfromJohnsHopkinsandbeinginductedintotheDeltaOmegaPublicHealthHonorSocietyin2017.Courtesy